Infectious Diseases Research

Below are current clinical trials.

273 studies in Infectious Diseases Research
(all studies, either open or closed).

Filter this list of studies by location, status and more.

1. Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)

   Scottsdale/Phoenix, Ariz.

   This is an efficacy and safety study of grazoprevir (MK-5172) in combination with elbasvir (MK-8742) with or without ribavirin (RBV) in participants with chronic hepatitis C virus (HCV) genotype (GT) 1, 4, or 6 infections who have failed prior therapy with pegylated interferon and RBV. The primary study hypothesis is that in at least one of the study arms, the percentage of participants achieving sustained viral response 12 weeks after the end of all study treatment (SVR12) will be superior to 58%.

2. Phase 3 Study With Dual Release Ciprofloxacin for Inhalation in Non-CF Bronchiectasis

   Rochester, Minn.

   The DRCFI treatment will influence the time to first pulmonary exacerbation compared to placebo.

3. A Study to Evaluate Acalabrutinib with Best Supportive Care in Participants Hospitalized with COVID-19 (Enrolling by Invitation Only)

   Rochester, Minn.

   The purpose of this study is to evaluate the safety and tolerability of Acalabrutinib suspension when delivered via a nasogastric tube and co-administered with a Proton Pump Inhibitor, in the treatment of COVID-19.

4. Research to Test Whether Doing Exercise Training Helps Lessen or Prevent the Longer-term Symptoms of COVID-19 Infection

   Jacksonville, Fla.

   The objectives of this study are to assess the ‘longer-term’ clinical, pulmonary, cardiac, functional, and psychosocial sequelae of COVID-19 survivorship, and to investigate whether exercise therapy enhances recovery of and/or improves pulmonary and cardiac function, exercise capacity, clinical status, and overall HRQoL in COVID-19 survivors.

    

    

5. A Study to Evaluate Early Detection of SARS-CoV-2/COVID-19 in High Risk Radiation Oncology Patients

   Rochester, Minn.

   The purpose of this study is to develop algorithms that will enable earlier identification and testing triggers for COVID-19 in otherwise asymptomatic patients, and to identify baseline characteristics from patients who ultimately test positive for COVID-19 that may predict clinical trajectory during the evolution of disease.

    

6. A Study to Evaluate the Feasibility of Rapid COVID-19 Testing in Disadvantaged Populations

   Rochester, Minn.

   The specific aims of the study are to:

   Aim 1. To determine the feasibility of a community-engaged research partnership to support rapid SARS-CoV-2 testing for symptomatic patients of all ages in the underserved population during the COVID-19 crisis. We will pilot a rapid testing strategy at OCHC using Mayo Clinic Laboratory (MCL) diagnostic processing.

   Aim 2. Compare the effectiveness of community-driven messaging in increasing uptake of rapid SARS-CoV-2 testing compared with usual sources of health information. We will draw a simple random sample of OCHC patients (N=1000, age 18+) with 1:1 randomization of communication about COVID-19 and availability of rapid testing from OCHC versus usual sources (control).

7. Will Making the HPV Vaccine Available at Mayo Clinic Express Care with Use of Electronic Point of Care Reminder Improve Overall Vaccination Rates Among an Empaneled Adolescent Population?

   Rochester, Minn.

   The purpose of this study is to determine if a medical record prompt at the time of a medical consult will help to address lapses in routine immunizations, including the HPV vaccine.

    

    

8. A Study to Evaluate the Performance of Chembio Diagnostics Systems, Inc. DPP® Zika IgM Assay System With Fingerstick Whole Blood (MVSS CBD002-18 PRO)

   Rochester, Minn.

   The purpose of this study is to support the use of fingerstick whole blood on the Chembio DPP® Zika IgM Assay System.

9. Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

   Scottsdale/Phoenix, Ariz.

   The purpose of this open-label extension of CDI-001 (subsequently referred to as PRISM 3) is to evaluate the safety and efficacy in reducing recurrence of CDI in adults who had a recurrence within 8 weeks of receiving CP101 or placebo in PRISM 3. Subjects who are experiencing recurrent CDI will undergo screening procedures. Subjects who meet eligibility criteria will be eligible to be enrolled in the extension study and administered CP101. Approximately 70 subjects will receive CP101. The treatment duration will be 1 day. Subjects will be monitored for recurrence of CDI, safety, and tolerability for 24 weeks following receipt of CP101. The primary efficacy and safety endpoints will be evaluated at 8 weeks post treatment, and all subjects will continue to be followed for an additional 16 weeks for safety and recurrence of CDI.

10. A Study to Compare COVID-19 Nasal Testing to Gastric, Bile, or Intestinal Testing

    Rochester, Minn.

    The primary aim of this study is to determine if there is any evidence of viral shedding within the gastrointestinal or pulmonary system in patients with a prior recent negative nasopharyngeal PCR test. This will be of critical importance to the practice of endoscopy during this pandemic as it will help:  1) determine if a pre-endoscopy testing strategy is adequate to ramp-up access to semi-urgent and eventually elective procedures, while allowing the decreased utilization of limited or costly personal protective equipment (e.g., N95 respirators) while still keeping the GI endoscopy staff safe; and 2) realize the false negative rate of pre-procedural testing, which is vital to inform procedural practice policy and operations.